Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) was up 12.1% on Tuesday . The company traded as high as C$3.49 and last traded at C$3.48. Approximately 51,060 shares traded hands during trading, an increase of 589% from the average daily volume of 7,410 shares. The stock had previously closed at C$3.10.
Eupraxia Pharmaceuticals Stock Performance
The business has a fifty day simple moving average of C$2.59 and a two-hundred day simple moving average of C$2.67.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
See Also
- Five stocks we like better than Eupraxia Pharmaceuticals
- What is a Stock Market Index and How Do You Use Them?
- Palantir Cracks $50, Is There Still Time to Get on Board?
- The 3 Best Blue-Chip Stocks to Buy Now
- Insider Buying Signals Upside for These 3 Stocks
- How to Evaluate a Stock Before Buying
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
